Gut microbiota-derived metabolites and multi-organ fibrosis: mechanisms, cross-organ signatures, and therapeutic opportunities
This narrative review maps associations between gut dysbiosis and multi-organ fibrosis but provides no primary data sufficient to establish causality or clinical effect magnitude.
| Population | Human patients and animal models with hepatic, pulmonary, cardiac, intestinal, or cutaneous fibrosis |
|---|---|
| Intervention | Modulation of gut microbiota and its metabolites (SCFAs, TMAO, bile acids) |
| Comparator | Not applicable — narrative review without formal comparator arm |
| Outcome | Hepatic fibrosis progression; Pulmonary fibrosis progression; Cardiac fibrosis progression; SCFA levels and association with fibrosis; TMAO accumulation and fibrotic severity; Bile acid pool dysbiosis and fibrosis; FMT/microbiota interventions on fibrosis (animal models) |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Hepatic fibrosis progression | no pooled effect size reported; qualitative association only | — | Low | — | |
| Pulmonary fibrosis progression | no pooled effect size reported; animal model data only | — | Very low | — | |
| Cardiac fibrosis progression | no pooled effect size reported; animal model data only | — | Very low | — | |
| SCFA levels and association with fibrosis | no pooled effect size reported; cross-sectional association only | — | Low | — | |
| TMAO accumulation and fibrotic severity | no pooled effect size reported; cross-sectional association only | — | Low | — | |
| Bile acid pool dysbiosis and fibrosis | no pooled effect size reported; mechanistic and cross-sectional data only | — | Low | — | |
| FMT/microbiota interventions on fibrosis (animal models) | no pooled effect size reported; direction inferred from narrative summary of animal studies only | — | Very low | — |
Context
Fibrosis accounts for approximately 45% of chronic disease deaths globally, with no approved therapies capable of reversing progression. The gut microbiota regulates gut-liver, gut-lung, gut-heart, and gut-skin axes via metabolites including SCFAs, TMAO, and bile acids. Identifying causal mechanisms is a prerequisite for therapeutic target development.
What the study showed
Cross-sectional population studies indicate association between dysbiosis (reduced SCFAs, TMAO accumulation, bile acid pool imbalance) and fibrosis severity across multiple organs. Animal experiments using germ-free mice, fecal microbiota transplantation, and specific strain interventions provided causal support for hepatic, pulmonary, cardiac, and cutaneous fibrosis. No primary numerical data with 95% CI is presented in the provided text — findings are qualitative syntheses of secondary literature.
How it was done
Narrative review published in Frontiers in Microbiology (2026). Integrates cross-sectional population studies, case-control studies, animal model experiments (germ-free colonization, FMT, strain interventions), and mechanistic molecular data. No systematic search protocol, standardized inclusion/exclusion criteria, independent data extraction, or formal risk-of-bias assessment is described.
Effect magnitude
No pooled effect size with 95% CI is reported in the provided text. Associations are described qualitatively without meta-analysis or quantitative synthesis.
Risk of bias
Narrative review without systematic search protocol — high risk of selection and publication bias (AMSTAR-2 not applied by authors). Human causality is not established; animal studies dominate the mechanistic base. Available text represents only introduction and initial discussion, without access to the full data synthesis.
What this study does NOT prove
This study does not prove causality between gut microbiota and fibrosis in humans, nor efficacy of any therapeutic intervention. It is not generalizable to clinical recommendations for microbiota modulation in fibrotic patients.
In clinical practice
No clinical intervention recommendation is supported by this study. Clinicians should note that gut dysbiosis is an associated marker of fibrosis severity, not a validated therapeutic target in randomized clinical trials. Monitoring metabolites such as TMAO may have future prognostic value but lacks standardization and clinical validation.
Limitations
Narrative review without systematic search protocol — high risk of selection and publication bias (AMSTAR-2 not applied by authors). Human causality is not established; animal studies dominate the mechanistic base. Available text represents only introduction and initial discussion, without access to the full data synthesis.
What is still missing
Randomized clinical trials evaluating specific microbiota interventions (probiotics, FMT, bile acid modulators) with histologically validated primary fibrotic outcomes in human populations with multi-organ fibrosis.
Technical appendix
Version history
- 1.0 · 2026-10-06 — Auto-generated under Evidence Standard v1.0